Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDUN phase 2 trial of AGA2115 in adults with osteogenesis imperfecta
NL-OMON61300Phase 2Not yet recruiting
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of AGA2115 in osteogenesis imperfecta (OI), sponsored by Angitia Biopharmaceuticals. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at Month 12. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
AGA2115
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NL-OMON61300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61300.